A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) Given by Mouth in Healthy Volunteers

Inclusion Criteria: * Healthy men, aged 18 to 45 years of age, inclusive * Body Mass Index (BMI) of 18 to 30 kilograms/meter square, inclusive Exclusion Criteria: * History or evidence of any medical condition potentially altering the absorption, metabolism or elimination of drugs * History of malignancy in the past 5 years * A history of clinically significant hypersensitivity (e.g. drugs, excipients) or allergic reactions * Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to first study drug administration * History or presence of clinically significant electrocardiogram (ECG) abnormalities or cardiovascular disease * Clinically significant abnormalities in laboratory test results * Confirmed resting pulse rate (PR) greater than 100 or less than 40 bpm * Confirmed systolic blood pressure (SBP) greater than 140 or less than 90 mm Hg, and diastolic blood pressure (DBP) greater than 90 or less than 50 mm Hg * Positive result on HIV1 and HIV2, hepatitis C (HCV) or hepatitis B (HBV) * History of any clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardio-vascular, endocrinological, ophthalmological, dermatological, hematological or allergic disease, metabolic disorder, hypofertility, cancer or cirrhosis * History or evidence of (neuro)muscular disorders * Hypersensitivity to itraconazole, to any of the other ingredients, or to any other triazole antifungal * Any other known contraindications to itraconazole